Curaleaf Holdings Files 6-K Report

Ticker: CURLF · Form: 6-K · Filed: 2024-08-08T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, sec-filing, reporting-update

TL;DR

Curaleaf filed a 6-K for Q2 2024, incorporating info into their F-10. Standard update.

AI Summary

Curaleaf Holdings, Inc. filed a Form 6-K on August 8, 2024, reporting for the period ending June 30, 2024. The filing indicates that the company is a foreign private issuer and will file annual reports under Form 40-F. Exhibit 99.1 from this report is incorporated by reference into their Form F-10 registration statement.

Why It Matters

This filing provides an update on Curaleaf's reporting status and incorporates information into their existing registration statement, which is relevant for investors tracking the company's regulatory compliance and financial disclosures.

Risk Assessment

Risk Level: low — This is a routine filing that primarily incorporates previously disclosed information and confirms reporting status, posing no immediate new risks.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report for the month of August 2024 and to incorporate Exhibit 99.1 into the company's existing Form F-10 registration statement.

What period does this report cover?

The report is for the period ending June 30, 2024.

Which form will Curaleaf Holdings, Inc. use for its annual reports?

Curaleaf Holdings, Inc. will file annual reports under cover of Form 40-F.

What is the Commission File Number for Curaleaf Holdings, Inc.?

The Commission File Number is 333-249081.

Where is Curaleaf Holdings, Inc.'s principal executive office located?

The principal executive office is located at 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada.

From the Filing

0001756770-24-000057.txt : 20240808 0001756770-24-000057.hdr.sgml : 20240808 20240807202104 ACCESSION NUMBER: 0001756770-24-000057 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Curaleaf Holdings, Inc. CENTRAL INDEX KEY: 0001756770 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-249081 FILM NUMBER: 241185596 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 781-451-0117 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: LEAD VENTURES INC. DATE OF NAME CHANGE: 20181023 6-K 1 q2246-kcover.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number: 333-249081 Curaleaf Holdings, Inc. (Name of Registrant) 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐    Form 40-F ☒ INCORPORATION BY REFERENCE Exhibit 99.1 to this Form 6-K of Curaleaf Holdings, Inc. (the “Company”) are hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-269109) of the Company, as amended or supplemented. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CURALEAF HOLDINGS, INC. (Registrant) Date: August 7, 2024 By: /s/ Peter Clateman Name: Peter Clateman Title: Chief Legal Officer EXHIBIT INDEX Exhibit Number Description 99.1 Unaudited Condensed Interim Consolidated Financial Statements as of June 30 , 2024 and December 31, 2023 and for the Three and Six Months Ended June 30 , 2024 and 2023 and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Six Months Ended June 30 , 2024 and 2023 99.2 CEO Certification of Interim Filings 99.3 CFO Certification of Interim Filings 99.4 Press Release dated August 7 , 2024 EX-99.1 2 q224-exx992xfsandmda.htm EX-99.1 Document Exhibit 99.2 CURALEAF HOLDINGS, INC. Condensed Interim Consolidated Financial Statements (Unaudited) As of June 30, 2024 and December 31, 2023 and For the Three and Six Months Ended June 30, 2024 and 2023 Page(s) Financial Statements: Condensed Interim Consolidated Balance Sheets (Unaudited) as of June 30, 2024 and December 31, 2023 3 Condensed Interim Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2024 and 2023 5 Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) for the three and six months ended June 30, 2024 and 2023 6 Condensed Interim Consolidated Statements of Temporary Equity and Shareholders’ Equity (Unaudited) for the six months ended June 30, 2024 and 2023 7 Condensed Interim Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2024 and 2023 8 Notes to Condensed Interim Consolidated Financial Statements (Unaudited) 10 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2024 and 2023 56 Curaleaf Holdings, Inc. Condensed Interim Consolidated Balance Sheets (Unaudited) (in thousan

View on Read The Filing